us > Maine > Oxford > Gilead > Latest & Local News
Gilead news
Gilead And Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced The Risk Of Death In ... - xm.com
Published on 2 June 2024 | 12:05 pm
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in ... - Yahoo Finance
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in ... Yahoo Finance
Published on 2 June 2024 | 12:00 pm
ASCO: Gilead sifts lung cancer data for efficacy crumbs - pharmaphorum
ASCO: Gilead sifts lung cancer data for efficacy crumbs pharmaphorum
Published on 2 June 2024 | 9:14 am
Gilead Sciences (NASDAQ:GILD) Shares Gap Down to $64.08 - Defense World
Gilead Sciences (NASDAQ:GILD) Shares Gap Down to $64.08 Defense World
Published on 2 June 2024 | 6:24 am
Gilead to present EVOKE-01 study data at ASCO meeting - TipRanks.com - TipRanks
Gilead to present EVOKE-01 study data at ASCO meeting - TipRanks.com TipRanks
Published on 1 June 2024 | 4:04 pm
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of ... - Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of ... Business Wire
Published on 1 June 2024 | 12:00 pm
Gilead drug fails to confirm its FDA approval in bladder cancer - The Business Journals
Gilead drug fails to confirm its FDA approval in bladder cancer The Business Journals
Published on 31 May 2024 | 9:55 pm
Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer - MedCity News
Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer MedCity News
Published on 31 May 2024 | 5:03 pm
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal - Yahoo Finance
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal Yahoo Finance
Published on 31 May 2024 | 5:01 pm
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival - Reuters
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival Reuters
Published on 31 May 2024 | 4:13 pm
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trial - WIBQ
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trial WIBQ
Published on 31 May 2024 | 3:16 pm
Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial - BioSpace
Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial BioSpace
Published on 31 May 2024 | 3:06 pm
Gilead's urothelial cancer trial fails to meet primary endpoint - Clinical Trials Arena
Gilead's urothelial cancer trial fails to meet primary endpoint Clinical Trials Arena
Published on 31 May 2024 | 3:00 pm
Gilead's Trodelvy Fails To Show Significant Survival Benefit - Finimize
Gilead's Trodelvy Fails To Show Significant Survival Benefit Finimize
Published on 31 May 2024 | 2:04 pm
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer W - Benzinga
Published on 31 May 2024 | 1:27 pm
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival - AOL
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival AOL
Published on 31 May 2024 | 12:18 pm
ASCO: Gilead looks for silver lining in Trodelvy's failed lung cancer trial. But will the FDA play ball? - FiercePharma
ASCO: Gilead looks for silver lining in Trodelvy's failed lung cancer trial. But will the FDA play ball? FiercePharma
Published on 31 May 2024 | 12:00 pm
Gilead's Trodelvy fails to meet main goal in late-stage cancer study - ETHealthWorld
Gilead's Trodelvy fails to meet main goal in late-stage cancer study ETHealthWorld
Published on 31 May 2024 | 11:56 am
Phase III trial miss shakes faith in Gilead's Trodelvy - The Pharma Letter
Phase III trial miss shakes faith in Gilead's Trodelvy The Pharma Letter
Published on 31 May 2024 | 11:32 am
Pharma firm Gilead has been called on to allow generic versions of its new HIV drug - Islander News.com
Pharma firm Gilead has been called on to allow generic versions of its new HIV drug Islander News.com
Published on 31 May 2024 | 9:06 am
Gilead's Trodelvy woes rise with failed bladder cancer trial - pharmaphorum
Gilead's Trodelvy woes rise with failed bladder cancer trial pharmaphorum
Published on 31 May 2024 | 7:39 am
Gilead's Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths - FiercePharma
Gilead's Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths FiercePharma
Published on 30 May 2024 | 10:20 pm
Gilead's Trodelvy fails to meet main goal in late-stage study - KDAL
Gilead's Trodelvy fails to meet main goal in late-stage study KDAL
Published on 30 May 2024 | 9:55 pm
Gilead's Trodelvy fails to meet main goal in late-stage study - xm.com
Gilead's Trodelvy fails to meet main goal in late-stage study xm.com
Published on 30 May 2024 | 9:01 pm
Gilead Provides Update on Phase 3 TROPiCS-04 Study - Yahoo Finance
Gilead Provides Update on Phase 3 TROPiCS-04 Study Yahoo Finance
Published on 30 May 2024 | 8:45 pm
Gilead Provides Update on Phase 3 TROPiCS-04 Study - Business Wire
Gilead Provides Update on Phase 3 TROPiCS-04 Study Business Wire
Published on 30 May 2024 | 8:45 pm
Cytiva rolls out new CAR-T manufacturing platform developed with Gilead's Kite - FiercePharma
Cytiva rolls out new CAR-T manufacturing platform developed with Gilead's Kite FiercePharma
Published on 30 May 2024 | 1:19 pm
Gilead Sciences appoints Houbara Communications as PR partner - Adgully
Gilead Sciences appoints Houbara Communications as PR partner Adgully
Published on 30 May 2024 | 9:22 am
Celebrities join campaigners in call for cheaper version of ‘gamechanger’ HIV drug for poorer countries - The Guardian
Celebrities join campaigners in call for cheaper version of ‘gamechanger’ HIV drug for poorer countries The Guardian
Published on 30 May 2024 | 7:13 am
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors MarketWatch
Published on 29 May 2024 | 8:45 pm
Gilead draws up $20M pact with cancer biotech Cartography - Fierce Biotech
Gilead draws up $20M pact with cancer biotech Cartography Fierce Biotech
Published on 28 May 2024 | 2:26 pm
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot" - Yahoo Finance
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot" Yahoo Finance
Published on 28 May 2024 | 1:50 pm
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years - The Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years The Motley Fool
Published on 28 May 2024 | 1:45 pm
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets ... - Business Wire
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets ... Business Wire
Published on 28 May 2024 | 11:00 am
The Handmaid's Tale Season 6's Actor Change Is A Big Step Forward For Gilead's Replacement - Screen Rant
The Handmaid's Tale Season 6's Actor Change Is A Big Step Forward For Gilead's Replacement Screen Rant
Published on 28 May 2024 | 2:20 am
Gilead FOCUS Program: Transforming Health Systems to Create Health Equity - Gilead Sciences
Gilead FOCUS Program: Transforming Health Systems to Create Health Equity Gilead Sciences
Published on 23 May 2024 | 9:46 pm
Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead - STAT
Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead STAT
Published on 23 May 2024 | 7:00 am
Gilead Sciences Hosts Inaugural Global Health Equity Summit - 3BL Media
Gilead Sciences Hosts Inaugural Global Health Equity Summit 3BL Media
Published on 21 May 2024 | 1:50 pm
Gilead Ordered to Show Attorney Bills in HIV Studies Breach Suit - Bloomberg Law
Gilead Ordered to Show Attorney Bills in HIV Studies Breach Suit Bloomberg Law
Published on 16 May 2024 | 7:00 am
The Balm In Gilead: Addressing Heart Health and High Blood Pressure in African American Communities - National Heart, Lung, and Blood Institute
The Balm In Gilead: Addressing Heart Health and High Blood Pressure in African American Communities National Heart, Lung, and Blood Institute
Published on 13 May 2024 | 7:00 am
AHF • AHF's 'Gilead for Greed' Lampoons Gilead Hypocrisy '...for Good' - AIDS Healthcare Foundation
AHF • AHF's 'Gilead for Greed' Lampoons Gilead Hypocrisy '...for Good' AIDS Healthcare Foundation
Published on 7 May 2024 | 7:00 am
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C - Yahoo Finance
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C Yahoo Finance
Published on 7 May 2024 | 7:00 am
Forbes Has Listed Gilead as One of America's Best - CSRwire.com
Forbes Has Listed Gilead as One of America's Best CSRwire.com
Published on 6 May 2024 | 7:00 am
Gilead HIV Drug Case Gets California Supreme Court Look (1) - Bloomberg Law
Gilead HIV Drug Case Gets California Supreme Court Look (1) Bloomberg Law
Published on 2 May 2024 | 7:00 am
Gilead HIV drug case to be heard by California court - STAT
Gilead HIV drug case to be heard by California court STAT
Published on 2 May 2024 | 7:00 am
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance
Published on 29 April 2024 | 7:00 am
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data - Clinical Trials Arena
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data Clinical Trials Arena
Published on 29 April 2024 | 7:00 am
Gilead writes $2.4B off Trodelvy as CEO underscores 'time of focused execution' - FiercePharma
Gilead writes $2.4B off Trodelvy as CEO underscores 'time of focused execution' FiercePharma
Published on 26 April 2024 | 7:00 am
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline - BioSpace
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline BioSpace
Published on 26 April 2024 | 7:00 am
Gilead gives up on $4.9B antibody magrolimab - Fierce Biotech
Gilead gives up on $4.9B antibody magrolimab Fierce Biotech
Published on 26 April 2024 | 7:00 am
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript - The Motley Fool
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript The Motley Fool
Published on 25 April 2024 | 7:00 am
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say Yahoo Finance
Published on 25 April 2024 | 7:00 am
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... - PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... PR Newswire
Published on 18 April 2024 | 7:00 am
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... - Yahoo Finance
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ... Yahoo Finance
Published on 15 April 2024 | 7:00 am
Gilead enlists Grammy nominee Raheem DeVaughn in HIV education, prevention initiative - FiercePharma
Gilead enlists Grammy nominee Raheem DeVaughn in HIV education, prevention initiative FiercePharma
Published on 12 April 2024 | 7:00 am
Ropes & Gray Advises Xilio Therapeutics in Gilead Sciences Exclusive Global License Agreement Up to $647.5 Million ... - Ropes & Gray LLP
Ropes & Gray Advises Xilio Therapeutics in Gilead Sciences Exclusive Global License Agreement Up to $647.5 Million ... Ropes & Gray LLP
Published on 27 March 2024 | 7:00 am
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn Pharmaceutical Technology
Published on 25 March 2024 | 7:00 am
Gilead's Win Upheld In Billion-Dollar HIV Drug Patent Case - Law360
Gilead's Win Upheld In Billion-Dollar HIV Drug Patent Case Law360
Published on 22 March 2024 | 7:00 am
Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years - FiercePharma
Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years FiercePharma
Published on 19 March 2024 | 7:00 am
Gilead CAR-T cancer therapy capacity to quadruple by 2026 - Reuters
Gilead CAR-T cancer therapy capacity to quadruple by 2026 Reuters
Published on 15 March 2024 | 7:00 am
AIDS advocates welcome 'greedy Gilead' to Miami with protests - FiercePharma
AIDS advocates welcome 'greedy Gilead' to Miami with protests FiercePharma
Published on 14 March 2024 | 7:00 am
CSRWire - Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant ... - CSRwire.com
Published on 13 March 2024 | 7:00 am
AHF • Protesters Keep Hammering 'Greedy Gilead' on Price Gouging - AIDS Healthcare Foundation
AHF • Protesters Keep Hammering 'Greedy Gilead' on Price Gouging AIDS Healthcare Foundation
Published on 12 March 2024 | 7:00 am
Gilead launches patient hub to 'expose' realities of living with metastatic breast cancer - FiercePharma
Gilead launches patient hub to 'expose' realities of living with metastatic breast cancer FiercePharma
Published on 11 March 2024 | 7:00 am
Gilead, Merus Ink Potential $1.5B Deal for T-Cell Engagers - BioSpace
Gilead, Merus Ink Potential $1.5B Deal for T-Cell Engagers BioSpace
Published on 7 March 2024 | 8:00 am
Why Gilead Sciences (GILD) Outpaced the Stock Market Today - Yahoo Finance
Why Gilead Sciences (GILD) Outpaced the Stock Market Today Yahoo Finance
Published on 7 March 2024 | 8:00 am
Key takeaways from Gilead's Innovation Talk at re:Invent 2023 | Amazon Web Services - AWS Blog
Key takeaways from Gilead's Innovation Talk at re:Invent 2023 | Amazon Web Services AWS Blog
Published on 6 March 2024 | 8:00 am
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers - Fierce Biotech
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers Fierce Biotech
Published on 6 March 2024 | 8:00 am
Abingworth to Provide Gilead Sciences Up To $210 Million in Funding | News & Events | Goodwin - Goodwin Procter
Abingworth to Provide Gilead Sciences Up To $210 Million in Funding | News & Events | Goodwin Goodwin Procter
Published on 5 March 2024 | 8:00 am
Gilead Secures $210M from VC to Build Trodelvy’s Clinical Case in NSCLC - BioSpace
Gilead Secures $210M from VC to Build Trodelvy’s Clinical Case in NSCLC BioSpace
Published on 1 March 2024 | 8:00 am
CymaBay Investor Alleges Gilead Buyout Filing Omits Conflicts - Bloomberg Law
CymaBay Investor Alleges Gilead Buyout Filing Omits Conflicts Bloomberg Law
Published on 1 March 2024 | 8:00 am
In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials - FiercePharma
In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials FiercePharma
Published on 29 February 2024 | 8:00 am
Howard University Awarded Nearly $1 Million for HIV Prevention Among Black Cisgender and Transgender Women - The Dig
Published on 29 February 2024 | 8:00 am
PhRMA taps Gilead CEO Dan O'Day as its new board chair - FiercePharma
PhRMA taps Gilead CEO Dan O'Day as its new board chair FiercePharma
Published on 21 February 2024 | 8:00 am
Dragonfly and Gilead enter partnership for cancer therapy - Pharmaceutical Technology
Dragonfly and Gilead enter partnership for cancer therapy Pharmaceutical Technology
Published on 16 February 2024 | 8:00 am
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials - Reuters
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials Reuters
Published on 15 February 2024 | 8:00 am
Gilead plans $4.3 billion deal to advance liver portfolio - European Pharmaceutical Review
Gilead plans $4.3 billion deal to advance liver portfolio European Pharmaceutical Review
Published on 14 February 2024 | 8:00 am
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion - Investopedia
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion Investopedia
Published on 12 February 2024 | 8:00 am
Gilead acquiring CymaBay and its liver disease drug for $4.3 billion - STAT
Gilead acquiring CymaBay and its liver disease drug for $4.3 billion STAT
Published on 12 February 2024 | 8:00 am
Gilead Sciences CEO on company's evolution and commitment to the Bay Area - San Francisco Business Times - The Business Journals
Gilead Sciences CEO on company's evolution and commitment to the Bay Area - San Francisco Business Times The Business Journals
Published on 12 February 2024 | 8:00 am
Gilead to buy CymaBay for $4.3 bln in bets on liver disease treatment - Reuters
Gilead to buy CymaBay for $4.3 bln in bets on liver disease treatment Reuters
Published on 12 February 2024 | 8:00 am
Gilead to Buy Liver Drugmaker for $4.3 Billion Equity Value - Bloomberg
Gilead to Buy Liver Drugmaker for $4.3 Billion Equity Value Bloomberg
Published on 12 February 2024 | 8:00 am
Gilead’s Q4 Revenue Slips on Weaker HIV and COVID-19 Sales, Amid Phase III Flops - BioSpace
Gilead’s Q4 Revenue Slips on Weaker HIV and COVID-19 Sales, Amid Phase III Flops BioSpace
Published on 7 February 2024 | 8:00 am
Tizona searching for new partner after Gilead declines buyout option - BioCentury
Tizona searching for new partner after Gilead declines buyout option BioCentury
Published on 7 February 2024 | 8:00 am
Gilead's at 'just the beginning' of cell therapy movement: exec - FiercePharma
Gilead's at 'just the beginning' of cell therapy movement: exec FiercePharma
Published on 7 February 2024 | 8:00 am
Gilead quarterly revenue drops 4%, oral COVID drug fails trial - Reuters
Gilead quarterly revenue drops 4%, oral COVID drug fails trial Reuters
Published on 6 February 2024 | 8:00 am
Gilead invests $320M in Arcus to increase stake to 33% - MM+M Online
Gilead invests $320M in Arcus to increase stake to 33% MM+M Online
Published on 31 January 2024 | 8:00 am
What to make of Gilead's Trodelvy troubles and Elevation Oncology's rise - STAT
What to make of Gilead's Trodelvy troubles and Elevation Oncology's rise STAT
Published on 25 January 2024 | 8:00 am
Gilead $247 Million Antitrust Deal Over HIV Drugs Gets Final Nod - Bloomberg Law
Gilead $247 Million Antitrust Deal Over HIV Drugs Gets Final Nod Bloomberg Law
Published on 20 January 2024 | 8:00 am
Cancer 'steals possibilities,' but Gilead is 'taking it back' in new oncology campaign - FiercePharma
Cancer 'steals possibilities,' but Gilead is 'taking it back' in new oncology campaign FiercePharma
Published on 16 November 2023 | 8:00 am
AHF • AHF Slams Gilead Profiteering - AIDS Healthcare Foundation
AHF • AHF Slams Gilead Profiteering AIDS Healthcare Foundation
Published on 7 November 2023 | 8:00 am
Mt. Gilead Road Improvements Project - City of Keller
Mt. Gilead Road Improvements Project City of Keller
Published on 2 November 2023 | 10:16 pm
Advancing Health Equity | Gilead - Gilead Sciences
Advancing Health Equity | Gilead Gilead Sciences
Published on 26 October 2023 | 7:00 am
Diversity in Clinical Trials - Gilead Sciences
Diversity in Clinical Trials Gilead Sciences
Published on 17 October 2023 | 12:49 pm
Zeroing In: Ending the HIV Epidemic | Gilead - Gilead Sciences
Zeroing In: Ending the HIV Epidemic | Gilead Gilead Sciences
Published on 21 August 2023 | 9:45 pm
Zeroing In: Ending the HIV Epidemic - Gilead Sciences
Zeroing In: Ending the HIV Epidemic Gilead Sciences
Published on 21 August 2023 | 9:45 pm